Work

Methodological considerations in clinical trials for new MDR-TB treatment regimens

Year: 2016

Type: article

Abstract: In contrast to the treatment of drug-susceptible tuberculosis (TB), the evidence base underpinning global guidelines for the treatment of multidrug-resistant (MDR) TB is very poor. This, combined with the lack of experience from previous trials and the nature of the disease, means that a number of methodological aspects are specific only to trials for new MDR-TB regimens. These aspects include the weight of evidence required to change policy and practice, the flexibility to make adaptations to an ongoing trial, the choice of patient population, the importance of internal control, the duration and frequency of follow-up, and safety monitoring of novel combinations of new and repurposed drugs.

Source: The International Journal of Tuberculosis and Lung Disease

DOI: 10.5588/ijtld.16.0061

Author: P. P. J. Phillips

Institutions: MRC Clinical Trials Unit at UCL, University College London, Medical Research Council

Language: English

Topic: Tuberculosis Research and Epidemiology

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Medical Research Council